Biohoo Life Science Directory
|
|
Acambis plc
Acambis is a vaccine company developing novel vaccines that address significant unmet medical needs or substantially improve upon current standards of care. In September 2008, Acambis was acquired by sanofi pasteur, the vaccines division of the sanofi-aventis Group, and is a wholly owned subsidiary of Sanofi Pasteur Holding. Sanofi Pasteur is a major player in the vaccines industry, with net sales of €2,778 million in 2007 and with leading vaccines in five areas: paediatric combination vaccines; influenza vaccines; adult and adolescent booster vaccines; meningitis vaccines; and travel, endemic and measles, mumps and rubella vaccines. It provided more than 1.6 billion doses of vaccine in 2007, making it possible to immunise more than 500 million people across the globe. Sanofi-aventis is a global pharmaceutical company engaged in the research, development, manufacture and marketing of healthcare products. Sanofi-aventis is listed on Paris Euronext and on the New York Stock Exchange. |
England
|
|
|
ACE BioSciences A/S
ACE BioSciences was established in 2001 and its pioneering proteomics expertise confers unique competitive advantage. The company is working to a clear set of objectives and has a focused strategy for success. It is lead by an internationally experienced team and staffed by highly motivated, well trained personnel. The company is well funded and has ambitious plans for growth. |
|
Denmark
|
|
|
Acuvax Ltd
Acuvax Ltd (ASX: ACU) represents a refocus of the Avantogen group, its current assets and the support of its investors and stakeholders on the most exciting and promising areas of the company's diagnostic and therapeutic profile, namely vaccine development. In the view of many experts, the next decade will see a significant ‘boost’ to vaccine sales, licensing activities and new product launches. There will be a new resurgence in vaccine sales and utilisation, making vaccines one of the fastest growing segments of the pharmaceutical market. Visiongain Research (2009) predicts that vaccine revenues will increase in size by several hundred percent between 2007 and 2023. The importance of vaccines in both developed and developing nations becomes underlined by epidemiological patterns and healthcare needs. The key growth driver for vaccines is their cost-effectiveness in combating disease. This situation will encourage greater use of vaccines by governments and private healthcare providers. New disease targets that could be mitigated through vaccination with current technologies, include high profile (and potentially profitable) targets such as Dengue Fever, West Nile Virus, Pandemic Flu, and various other emerging infectious diseases. Through Acuvax’s current and valuable investment in Hawaii Biotech Inc , a portfolio company in the Acuvax family of investments, and new potential opportunities sourcing exciting Australian technologies in the vaccine space, we have noted preventative medicine offers significant increases in quality of life and reduction of healthcare expenditure that can result from prophylaxis. Acuvax is positioning itself within the industry, responding with innovative products, making full use of technological advances in biotechnology. |
|
USA
|
|
|
Affiris GmbH
AFFiRiS identifies and develops tailor-made vaccines based on peptide antigens. As compared to recombinant protein products, peptides have the intrinsic advantage to be available in relatively short time frames at relatively low costs from established contract manufacturers. To achieve product launch as quickly as possible, AFFiRiS is working with streamlined processes and tightly controlled milestones and timelines. |
|
Austria
|
|
|
ALK-Abello A/S
ALK-Abello is the world-leading producer of pharmaceuticals for specific allergy vaccination. Not only do our allergy vaccines treat the allergic symptoms, but also the underlying causes of allergy and at the same time they prevent asthma. ALK-Abello has been active in allergy vaccination since 1923. In recent years, we have pursued a product development strategy of extending the current market of specialist administered subcutaneous vaccination to orally delivered alternatives. ALK-Abello's pipeline contains tablet-based products based on natural allergens against grass pollen and house dust mites. ALK-Abello has more than 1.200 employees with subsidiaries in several European countries, in the USA and in China. Headquarters is in Hoersholm, Denmark. |
|
Denmark
|
<<
Start <
Prev 1 2 3 4 5 6 7 8 9 10 Next >
End >>
